Skip to content
value.today

Quoin Pharmaceuticals, Ltd.

QNRX
No market cap data
Compare
World rank
—
no current market cap
Revenue
—
For year ending December-2025
Net income
$-16 M
SEC filing
Employees
—

Quoin Pharmaceuticals, Ltd. in brief

Quoin Pharmaceuticals, Ltd. is a listed company in the Biotechnology industry, based in Ashburn, Virginia, USA. Its shares trade under the symbol QNRX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Quoin Pharmaceuticals, Ltd.

We are a late-stage clinical specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases for which there are currently either no approved or very limited treatments or cures. Our lead product, QRX003, is under clinical development as a potential treatment for Netherton Syndrome, a rare hereditary genetic disease. QRX003 is entering pivotal registrational clinical testing under an open Investigational New Drug application with the Food and Drug Administration. We have opened six clinical sites in the United States along with international sites that are being opened in the UK, Spain, France and the Netherlands. QRX003 is currently being tested in seven pediatric NS patients in investigator-initiated studies in Ireland, Austria, the Netherlands and New Zealand. QRX003 is also being developed as a potential treatment for Peeling Skin Syndrome with the first subject being treated in New Zealand. We are in the process of expanding this study to include up to an additional five pediatric subjects. We entered into a Research Agreement with the Queensland University of Technology in Australia, under which we have obtained an option for a global license to QRX008 for the potential treatment of scleroderma, as well as a Research Agreement with The School of Pharmacy at University College Cork for the development of novel topical formulations of rapamycin (sirolimus) as potential treatments for a number of rare and orphan diseases for which there are either limited or no approved therapies or cures, including microcystic lymphatic malformations, venous malformations and angiofibromas among others. We have also entered into 9 commercial partnerships for QRX003 spanning 61 countries outside of our core commercial territories of the U.S., Western Europe and Japan.

From the company's annual report filed with the US SEC: read the report

Quoin Pharmaceuticals, Ltd. timeline

4 events, 2016–2021
  1. 2016
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. ✎
    Renamed Cellect Biotechnology Ltd.
    Formerly Cellect Biomed Ltd..
  4. 🔔
    Initial public offering as Cellect Biotechnology Ltd.
    Final prospectus filed with the SEC on 1 August 2016; shares registered for exchange trading on 27 July 2016.
  5. 2021
  6. ✎
    Renamed Quoin Pharmaceuticals, Ltd.
    Formerly Cellect Biotechnology Ltd..

Events of Quoin Pharmaceuticals, Ltd. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

Not enough history yet.

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2017: revenue —, net income $-8M—FY17Fiscal year ending Dec 2019: revenue —, net income $-2M—FY19Fiscal year ending Dec 2020: revenue —, net income $-2M—FY20Fiscal year ending Dec 2021: revenue —, net income $-21M—FY21Fiscal year ending Dec 2022: revenue —, net income $-9M—FY22Fiscal year ending Dec 2023: revenue —, net income $-9M—FY23Fiscal year ending Dec 2024: revenue —, net income $-9M—FY24Fiscal year ending Dec 2025: revenue —, net income $-16M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025———$-16M—
Dec 2024———$-9M—
Dec 2023———$-9M—
Dec 2022———$-9M—
Dec 2021———$-21M—
Dec 2020———$-2M—
Dec 2019———$-2M—
Dec 2017——$-7M$-8M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-14M————
Dec 2024$-8M————
Dec 2023$-8M————
Dec 2022$-8M————
Dec 2021$-6M——$-0.01—
Dec 2020$-1M——$-0.70—
Dec 2019$-1M——$-0.52—
Dec 2017$-5M$0M$-5M——

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-2M—Dec ’24Three months to Mar 2025: revenue —, net income $-4M—Mar ’25Three months to Jun 2025: revenue —, net income $-4M—Jun ’25Three months to Sep 2025: revenue —, net income $-4M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-4M—Dec ’25Three months to Mar 2026: revenue —, net income $-5M—Mar ’26Three months to Jun 2026: revenue —, net income $-5M—Jun ’26Three months to Sep 2026: revenue —, net income $-5M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Quoin Pharmaceuticals, Ltd. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
—
Net income
$-16 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$20 M
Total liabilities
$7 M
Total equity
$13 M

As of December-2025

Top 25 institutional investors in Quoin Pharmaceuticals, Ltd.#

As of Sep 30, 2026
25 institutions held 2.7 M shares on Sep 30, 2026. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Quoin Pharmaceuticals, Ltd.
#InstitutionShares heldChange (shares)ValueFiled
1Stonepine Capital Management, LLC252,434+52,948 (+26.54%)$1 MNov 13, 2026
2Nantahala Capital Management, LLC236,234New$1 MNov 13, 2026
3Sphera Funds Management LTD.236,234New$1 MNov 16, 2026
4AIGH Capital Management LLC236,234+166,234 (+237.48%)$1 MNov 2, 2026
5Stempoint Capital LP236,234New$1 MNov 16, 2026
6Millennium Management LLC236,227+123,904 (+110.31%)$1 MNov 16, 2026
7Ikarian Capital, LLC211,5380 (0.00%)$1 MNov 16, 2026
8Empery Asset Management, LP204,910New$1 MNov 16, 2026
9Dauntless Investment Group, LLC193,937-21,050 (-9.79%)$1 MNov 16, 2026
10J. Goldman & Co LP190,192New$1 MNov 16, 2026
11Diadema Partners LP146,446New$1 MNov 16, 2026
12DAFNA Capital Management LLC132,156New$1 MNov 16, 2026
13Boothbay Fund Management, LLC59,8380 (0.00%)$0 MNov 16, 2026
14Nano Cap New Millennium Growth Fund L P50,000New$0 MNov 13, 2026
15Citadel Advisors LLC20,307New$0 MNov 16, 2026
16Jane Street Group, LLC19,456New$0 MNov 12, 2026
17Morgan Stanley8,0000 (0.00%)$0 MNov 13, 2026
18Rhumbline Advisers3,169+837 (+35.89%)$0 MNov 10, 2026
19GAMMA Investing LLC3,116+2,677 (+609.79%)$0 MOct 8, 2026
20Nuveen, LLC437New$0 MNov 10, 2026
21Arax Advisory Partners171New$0 MNov 12, 2026
22Tower Research Capital LLC (TRC)136New$0 MNov 16, 2026
23SBI Securities Co., Ltd.128-227 (-63.94%)$0 MOct 22, 2026
24Caitong International Asset Management Co., Ltd9New$0 MOct 29, 2026
25Nisa Investment Advisors, LLC4New$0 MOct 20, 2026

Mutual funds holding Quoin Pharmaceuticals, Ltd.#

2 funds hold shares worth $0 M (about 0.1% of the company). Since their previous reports 0 added shares and 0 sold.
Mutual funds holding Quoin Pharmaceuticals, Ltd.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 abrdn World Healthcare Fundabrdn Inc.40,400$0 M0.06%0.03%no changeJun 30, 2026
🇺🇸 abrdn Life Sciences Investorsabrdn Inc.34,600$0 M0.05%0.02%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 2 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Quoin Pharmaceuticals, Ltd.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$180 K
4 purchases, 4 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$180 K
open market only
Insiders on file
6
since
$350 K-$217$0Jun 2024: bought $0 (0 trades), sold $217 (1 trades)Jun 24Sep 2024: bought $81 K (13 trades), sold $0 (0 trades)SepDec 2024: bought $350 K (4 trades), sold $0 (0 trades)DecOct 2025: bought $129 K (1 trades), sold $0 (0 trades)OctAug 2026: bought $180 K (4 trades), sold $0 (0 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
Quoin Pharmaceuticals, Ltd.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Denise P. CarterChief Operating Officer, DirectorBuy+20,490$4.880—37,709Form 4
filed Anthony James CulverwellDirectorBuy+6,146$4.880$30 K40,364Form 4
filed Michael MyersChief Executive Officer, DirectorBuy+20,490$4.880$100 K37,713Form 4
filed Sally Bridget LawlorChief Financial OfficerBuy+10,244$4.880$50 K10,684Form 4
filed Dennis LangerDirectorGrant or award+34,534$5.150$178 K56,243Form 4
filed Anthony James CulverwellDirectorGrant or award+31,352$5.150$161 K34,218Form 4
filed Dennis LangerDirectorBuy+15,152$8.490$129 K15,153Form 4
filed Michael MyersChief Executive Officer, DirectorBuy+555,556$0.450$250 K602,808Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Quoin Pharmaceuticals, Ltd.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
23,705
0.0% of shares · 1.9 days to cover
Reg SHO threshold list
6 days
in the last 90 days
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1.67-for-1 split ; 12.5-for-1 split

Trading halts

  • 2026-11-17 15:19 UTC, code LUDP, resumed 15:24 UTC
  • 2026-06-24 14:06 UTC, code LUDP, resumed 14:11 UTC
  • 2026-06-24 13:57 UTC, code LUDP, resumed 14:02 UTC
  • 2026-03-25 13:42 UTC, code LUDP, resumed 13:47 UTC
  • 2026-03-25 13:33 UTC, code LUDP, resumed 13:38 UTC

Fails to deliver

  • : 774 shares at $4.16
  • : 666 shares at $4.18
  • : 465 shares at $4.00
  • : 460 shares at $4.01
  • : 22,887 shares at $3.98

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Quoin Pharmaceuticals, Ltd. scorecard#

Passes 1 of the 6 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✗Net income higher than five years earlier-$16 M-$16 M in fiscal 2025 against -$2 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$16 MNet income -$16 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-141.6%-141.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities3.6×Current ratio 3.61 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Quoin Pharmaceuticals, Ltd.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in thousands of each column's currency; per-share figures in the column's currency; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Quoin Pharmaceuticals, Ltd.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025 · USDFY 2024to Dec 31, 2024 · USDFY 2023to Dec 31, 2023 · USDFY 2022to Dec 31, 2022 · USDFY 2021to Dec 31, 2021 · USDFY 2020to Dec 31, 2020 · USDFY 2019to Dec 31, 2019 · USDFY 2018to Dec 31, 2018 · ILSFY 2017to Dec 31, 2017 · ILSFY 2016to Dec 31, 2016 · ILS
Income statement
Revenue————000———
Research and development9,8033,6033,3082,6731,563244r46r13,513r−11,503r8,256
Selling, general and administrative6,4885,9266,0716,5854,5001,4261,5153,7303,4441,299
Total costs and expenses———————29,24724,43315,944
Operating income—————−4,353−6,462−29,247−24,433−15,944
Interest and finance income482558————2,0249,154101660
Interest expense and finance costs————1,09047r425203,89233
Other non-operating income (expense)486566692−124−15,400−425————
Income before tax−15,805−8,962————————
Net income including minority interests−15,805−8,962−8,687−9,381−21,463−2,095r−1,560r−20,113−28,224−15,317
Net income attributable to shareholders−15,805−8,962−8,687−9,381−21,463−2,095−1,560———
Earnings per share, basic————-0.01-0.70-0.52———
Earnings per share, diluted————-0.01-0.70-0.52———
Shares, weighted average (basic)————1,5851,201r1,201r12911291
Shares, weighted average (diluted)————1,5851,2011,201———
Balance sheet
Cash and cash equivalents3,8183,6232,4012,8617,483324r5,632r17,80913,7346,279
Short-term investments14,92710,434————————
Receivables—————5.03.030——
Other current assets1,262869591517——————
Current assets20,00714,92611,28613,3708,198r465r5,37518,62528,55132,397
Property, plant and equipment—————3843731,5441,3441,373
Right-of-use (leased) assets———————1,614——
Other intangible assets383483583705809913————
Non-current assets—————7257942,0131,8221,513
Total assets20,39115,70912,16914,4589,3571,378r6,16920,63830,37333,910
Accounts payable1,262906527606923—————
Current liabilities5,5474,1813,5813,5284,5769291,0524,8994,0993,485
Lease liabilities (non-current)—————122196———
Non-current liabilities—————5028241,816——
Total liabilities7,2716,5056,5057,0518,7007,985————
Retained earnings−70,970−55,166−46,203−37,517−28,070−6,607r−29,185−84,056−63,943−35,719
Shareholders' equity13,1209,2055,6647,407657−6,607−4,512———
Total equity—————4,6594,29313,92318,85228,487
Total liabilities and equity20,39115,70912,16914,4589,3571,378r6,16920,63830,37333,910
Shares outstanding528.91.00.4r3,3551,201r224130120r108
Cash-flow statement
Depreciation and amortization—————109108459372350
Share-based compensation1,1471,2591,09576402297844,5375,3841,552
Cash from operating activities−13,541−7,857−7,864−8,481−5,720−1,339r−1,299r−23,635−17,770−14,412
Capital expenditure—————−103−36−656−266−1,265
Cash from investing activities−4,278−1,8882,188−10,149−625−125r−3113,70810,091−18,012
Shares issued18,61411,568———2,8606,47912,36014,38134,917
Cash from financing activities18,01410,9685,21714,00813,5041,787r1,299r12,75915,81334,924
Exchange-rate effect on cash—————393−3271,243−679−134
Change in cash1951,222———−355864,0757,4552,366
Report10-K10-K10-K10-K10-K20-F20-F20-F20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Quoin Pharmaceuticals, Ltd.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 6 · Material agreement 3 · Unregistered share sale 2 · Shareholder rights changed 1 · Shareholder vote 3 · Results announced 7

Quoin Pharmaceuticals, Ltd.: events reported to the SEC
FiledWhat happenedFiling
Shareholder vote8-K
Results announced8-K
Material agreement8-K
Material agreementUnregistered share sale8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Directors and officersShareholder rights changedShareholder vote8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Quoin Pharmaceuticals, Ltd.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2026$50 MPrivate placement after listing$50 to $250 million33equity, optionsSEC
Oct 2025$105 MPrivate placement after listing$50 to $250 million27equity, optionsSEC
Jan 2018$4 MPrivate placement after listing$2 to $10 million3optionsSEC
Sep 2017$4 MNo. 1$2 to $10 million18optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Quoin Pharmaceuticals, Ltd.#

$60 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues, medical/disease research/clinical labs and pharmacy.

Lobbying, 2025
$60 K
#1,342 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$60 K
  • Health Issues3 reports
  • Medical/Disease Research/Clinical Labs3 reports
  • Pharmacy3 reports

Lobbying firms hired in 2025

Forward Global $60 K

Quoin Pharmaceuticals, Ltd.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$60 K—3
2025$60 K—4

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Quoin Pharmaceuticals, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Quoin Pharmaceuticals, Ltd.#

1 labor condition applications certified in fiscal 2025 for 1 positions.

Certified, FY2025
1
#2,048 among companies on value.today
Worker positions
1
Median wage offered
—
a year, full-time
Applications filed
1
Quoin Pharmaceuticals, Ltd.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
DirectorFinancial Managers1—

Where: Brooklyn, NY 1

Quoin Pharmaceuticals, Ltd.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202511—1
FY202311—1
FY202111—1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Quoin Pharmaceuticals Inc.

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Quoin Pharmaceuticals, Ltd.🇺🇸————
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Quoin Pharmaceuticals, Ltd.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Quoin Pharmaceuticals, Ltd.'s ranking on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Quoin Pharmaceuticals, Ltd.? Suggest a correction